1. Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing PCI XU H et al. Chin J Cardiol. 2013;41(3):205-209.

2. Revascularization may cause irreversible myocardial injuries About one-third of all elective PCI procedures are associated with significant myocardial injury, which has been linked to increased subsequent mortality.

3. Beneficial effects of trimetazidine therapy during PCI Methods  106 patients with unstable angina pectoris who underwent successful elective PCI were randomly assigned to standard therapy or trimetazidine treatment (60-mg loading dose prior to PCI followed by 20 mg tid after PCI on top of standard therapy).  Primary end point, cTnI levels, measured before and at 16-18 hours after PCI.  Secondary end points: Left ventricular (LV) function evaluated by echocardiography MACE (death, reinfarction, and target vessel revascularization) XU H et al. Chin J Cardiol. 2013;41(3):205-209.

4. Results Postprocedural cTnI levels were significantly reduced in the trimetazidine group compared with the control group (P< 0.05). Beneficial effects of trimetazidine therapy during PCI XU H et al. Chin J Cardiol. 2013;41(3):205-209. -92%

5. Results Beneficial effects of trimetazidine therapy during PCI XU H et al. Chin J Cardiol. 2013;41(3):205-209.

6. Conclusion Trimetazidine can reduce the post-PCI cTnI release and improve LV function after PCI in patients with unstable angina pectoris. Beneficial effects of trimetazidine therapy during PCI XU H et al. Chin J Cardiol. 2013;41(3):205-209. Discussion

7. Conclusion About one-third of all elective PCI procedures are associated with significant myocardial injury, which has been linked to increased subsequent mortality. Trimetazidine can effectively reduce PCI-associated myocardial damage, and has a protective effect on the myocardium. These benefits could be linked to the mode of action of trimetazidine MR. By providing a 33% increase in cellular energy, trimetazidine MR protects cardiomyocytes against ischemia.